Medtronic Boosts Revenue by Nearly Double Digits in Q4

Why It Matters

The results signal Medtronic’s successful capture of a fast‑growing electrophysiology market, boosting earnings potential and reinforcing its competitive position in cardiovascular medtech.

Key Takeaways

• Cardiac ablation revenue surged 78% globally, 124% in the U.S.
• Pulsed‑field ablation sales grew 145% worldwide, despite slower Q2 pace
• Medtronic’s FY26 revenue hit $36.36 billion, up 8.4% YoY
• Forecast FY27 organic growth of 6.75‑7.25% with $250 million tariff impact
• M&A adds $150 million inorganic revenue, including $585 million CathWorks deal

Pulse Analysis

Medtronic’s fourth‑quarter earnings underscore a pivotal shift toward high‑margin cardiovascular technologies, particularly cardiac ablation solutions. The 78% global growth in ablation revenue, driven by a 124% surge in the United States, reflects both strong physician adoption and the company’s strategic focus on expanding its electrophysiology portfolio. By leveraging its pulsed‑field ablation (PFA) platform, Medtronic captured market share from rivals, positioning itself as a leader in a segment projected to exceed $10 billion in annual sales within the next five years.

The competitive landscape for PFA is intensifying, with Boston Scientific, Johnson & Johnson, and Abbott racing to innovate. Medtronic’s 145% global increase in PFA sales, despite a slower pace than the earlier quarter’s 300% jump, demonstrates sustained momentum and validates its investment in next‑generation ablation technologies. This growth not only diversifies Medtronic’s revenue base but also enhances its bargaining power with hospitals seeking comprehensive electrophysiology solutions, potentially driving higher pricing power and longer‑term contracts.

Looking ahead, Medtronic projects FY27 organic revenue growth of 6.75‑7.25%, while accounting for a $250 million tariff impact. The company’s aggressive M&A strategy—highlighted by the $585 million CathWorks acquisition and a $650 million SPR Therapeutics deal—adds an estimated $150 million of inorganic revenue. These moves aim to broaden the device pipeline and accelerate entry into emerging therapeutic areas, reinforcing investor confidence in Medtronic’s ability to sustain double‑digit top‑line growth amid a dynamic regulatory and macroeconomic environment.